Monoclonal Antibodies: A Therapeutic Option for the Treatment of Ophthalmic Diseases of the Eye Posterior Segment

Authors

  • Catalina Ayón Universidad de Costa Rica
  • Daniel Castán Universidad de Costa Rica
  • Adrián Mora Universidad de Costa Rica
  • Dunia Naranjo Universidad de Costa Rica
  • Francini Obando Universidad de Costa Rica
  • Juan José Mora Universidad de Costa Rica https://orcid.org/0000-0003-3542-0649 (unauthenticated)

DOI:

https://doi.org/10.33084/bjop.v5i3.2095

Keywords:

Eye, Posterior segment disease, Adverse effects, Monoclonal antibody, Intravitreal therapy

Abstract

The eye is an organ that allows us to observe the outside world. Pathologies of the eye's posterior segment, such as glaucoma, macular degeneration, diabetic retinopathy, uveitis, and retinoblastoma, cause vision loss. Traditional treatments consist of applying topical medications that do not penetrate properly or using high doses that generate adverse effects. Different laser surgeries stop the pathology's progression but do not allow visual improvement. So, an alternative is to use monoclonal antibodies, proteins produced by different processes that selectively bind to metabolites associated with diseases, reducing the adverse effects of traditional treatments and improving the application of the drug in the area. The two main molecular targets are TNF (adalimumab, infliximab, and certolizumab pegol) and VEGF (bevacizumab and ranibizumab); other possibilities are under investigation.

Views: 641Downloads: 604

Downloads

Download data is not yet available.

Downloads

Published

08/31/2022

How to Cite

1.
Ayón C, Castán D, Mora A, Naranjo D, Obando F, Mora JJ. Monoclonal Antibodies: A Therapeutic Option for the Treatment of Ophthalmic Diseases of the Eye Posterior Segment. Borneo J Pharm [Internet]. 2022 Aug. 31 [cited 2026 Nov. 18];5(3):229-46. Available from: https://journal.umpr.ac.id/index.php/bjop/article/view/2095

Similar Articles

191-200 of 202

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)